Q-omics provides the consensus-scored MT-RNR2 profile across patient tissues and cancer cell-line models. MT-RNR2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MT-RNR2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MT-RNR2 RNA expression shows 18,577 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, COAD, and ACC as cancer lineages where MT-RNR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-RNR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-RNR2 survival associations across molecular data types. MT-RNR2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-RNR2 RNA expression–survival associations across cancer types. High MT-RNR2 expression shows unfavorable associations in UCS and LUAD, but favorable associations in ACC, LUSC, LGG and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MT-RNR2 RNA expression.
This table summarizes MT-RNR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MT-RNR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-RNR2 shows lower tumor expression in COAD, KIRC, LIHC, BRCA and HNSC and higher tumor expression in KICH. The COAD box plot shows higher MT-RNR2 RNA expression in normal versus tumor tissue (log2 FC = −1.603, t-test p < 0.001).
This table shows molecular features associated with MT-RNR2 in patient tissues and cancer cell lines. In patient samples, MT-RNR2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
